Iterum Therapeutics Plc (ITRM)

$0.03 -0.04 (-57.39%)
Market Cap 1.60M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.88
Volume 65,735,500
Avg Vol 19,797,338
Day's Range N/A - N/A
Shares Out 53.29M
Stochastic %K 2%
Beta 2.96
Analysts Hold
Price Target $9.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
DollerADay
DollerADay Aug. 3 at 2:33 PM
$ITRM from the Shionogi’s call this morning and earnings deck. Orlynvah fits so obviously well, it’s funny: * 160-person U.S. commercial platform already built with payer and distribution infrastructure—ideal for launching an oral outpatient anti-infective. The Covid drug alone doesn’t justify the cost. * Clear portfolio gap: strong hospital AMR franchise, but no approved oral resistant UTI product. Orlynvah fits naturally. * AMR is a core strategy, highlighted by Shionogi’s No. 2 global AMR ranking and growing infectious disease business. * Focus on oral hospital-to-home therapy mirrors Orlynvah’s step-down potential and outpatient treatment strategy. Taken together, today’s deck reinforces that Shionogi has deliberately built the commercial infrastructure, infectious disease focus, and AMR strategy that an asset like Orlynvah would complement exceptionally well. The strategic logic of adding an FDA-approved oral antibiotic is like bringing an umbrella in a rain storm.
1 · Reply
Amb8675309
Amb8675309 Aug. 3 at 7:58 AM
$ITRM BOD probably started thinking liquidation after 1st proxy no vote. CF was floundering in getting a deal to close, in large part because of RLN CoC multiplier- a problem created by a CF decision to get a loan with a steep price from a sophisticated BP entity. The delay on the launch may not be deliberate burning down of cash flow when viewed against the stupid decision to not pursue the “easy money” indication of Orly for step down on a cUTI discharge. All of these mistakes may be due to inexperienced CEO. Interestingly, whether Fishman planned it or the board imposed it doesn’t change the fundamental asset thesis at all. The sulopenem patent estate, the FDA approval, the clinical data, the cUTI opportunity — none of that depends on whether Fishman was a strategic genius or a desperate CEO who got fired.
0 · Reply
Gur001
Gur001 Aug. 3 at 7:42 AM
$ITRM Whats the update on liquidation guys? I been busy for last 3 weeks. please let me know in few words. Are we done or there is still hope 🙏
1 · Reply
Amb8675309
Amb8675309 Aug. 3 at 4:27 AM
$ITRM The relationship between the board and Teneo almost certainly predated the March 27 filing — boards in this situation engage restructuring advisors weeks or months before a public filing. That engagement was at the board level, not Fishman’s initiative. Fishman may not have been fully in the loop on the liquidation planning until relatively late. The “planned controlled transfer” framing that Stocktwits users found compelling was reading strategic intent into what was actually a board-level decision made after management failed to achieve a bilateral sale. Teneo wasn’t Fishman’s plan B — Teneo was the board’s plan after Fishman’s plan A failed.
2 · Reply
Amb8675309
Amb8675309 Aug. 3 at 4:23 AM
$ITRM revised thesis: BOD lost patience with CF & decided to go to liquidation- which eliminates the CEO/CFO positions- aka he “resigns”. Why? Maybe he’s not a tactical genius: 1) He took the RLN deal in Jan/2020, with NO CRL protection clause & an 8x CoC multiplier=structurally terrible deal that left the company catastrophically exposed to exactly the scenario that materialized( a CRL). 2) After the 2021 CRL for the uUTI, he did not pursue cUTI simultaneously(the far more VALUABLE market) & instead he spends 3 yrs & most of the co. remaining $ fixing the uUTI CRL. 3)He 🔥 10 months $ flow before launching via Eversana in 8/25, with approx. $11M in cash: an amount any experienced BP CEO would recognize as insufficient to fund a meaningful antibiotic launch to ➡️sustainable revenues. That is not the track record of a strategist. This was someone who was consistently behind the curve, making reactive decisions under capital pressure, and ultimately running out of road.
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 10:38 PM
$ITRM Shionogi coming in at 38%- highest match- same doctor writing IV script in hospital now can prescribe Orly- send patient home 2 days early- easy:have to sell one doctor on 2 different Shionogi meds if they buy Orly➡️less oral step down scripts for GSK/ Tebi. CEO of Shionogi committed to expanding US operations- whatever the cost. PFE doesn’t want GSK to win &just shelve cUTI Orly pathway➡️cuts down on PFE royalties- Better: Shionogi buys Orly- and now in outpatient setting all those new outpatient Shionogi reps have something other than a COVID-19 oral drug to sell. RLNs: most likely will walk away for a pay off of between $5-20Mil tops. Call it $80-100Mil to pay off all creditors. That leaves rest for shareholders. most shareholders happy and less likely to sue- maybe not me, but rest will be happy they put their hand in the fire and only singed their arm hairs.. $500MIL /52.8 Mil shares= $9.46/share Close to @yellowjacker estimates
2 · Reply
BTG007
BTG007 Aug. 2 at 9:51 PM
$ITRM threw all y’all’s numbers and theories into AI- that BARDA contract gives Shionogi the win-
1 · Reply
Toptopy
Toptopy Aug. 2 at 9:42 PM
$ITRM Effective on 01/08/2026 last update 29/07/2026
0 · Reply
EarlyRetirement0077
EarlyRetirement0077 Aug. 2 at 9:18 PM
$ITRM why am I not a millionaire already?
1 · Reply
BTG007
BTG007 Aug. 2 at 9:08 PM
$ITRM the RLNs apparently did hire a lawyer- just look it up- you have to pay to see it- anyways, they hired an expensive attorney for a reason- no one works on a case if it’s just about 100K
1 · Reply
Latest News on ITRM
No data available.
DollerADay
DollerADay Aug. 3 at 2:33 PM
$ITRM from the Shionogi’s call this morning and earnings deck. Orlynvah fits so obviously well, it’s funny: * 160-person U.S. commercial platform already built with payer and distribution infrastructure—ideal for launching an oral outpatient anti-infective. The Covid drug alone doesn’t justify the cost. * Clear portfolio gap: strong hospital AMR franchise, but no approved oral resistant UTI product. Orlynvah fits naturally. * AMR is a core strategy, highlighted by Shionogi’s No. 2 global AMR ranking and growing infectious disease business. * Focus on oral hospital-to-home therapy mirrors Orlynvah’s step-down potential and outpatient treatment strategy. Taken together, today’s deck reinforces that Shionogi has deliberately built the commercial infrastructure, infectious disease focus, and AMR strategy that an asset like Orlynvah would complement exceptionally well. The strategic logic of adding an FDA-approved oral antibiotic is like bringing an umbrella in a rain storm.
1 · Reply
Amb8675309
Amb8675309 Aug. 3 at 7:58 AM
$ITRM BOD probably started thinking liquidation after 1st proxy no vote. CF was floundering in getting a deal to close, in large part because of RLN CoC multiplier- a problem created by a CF decision to get a loan with a steep price from a sophisticated BP entity. The delay on the launch may not be deliberate burning down of cash flow when viewed against the stupid decision to not pursue the “easy money” indication of Orly for step down on a cUTI discharge. All of these mistakes may be due to inexperienced CEO. Interestingly, whether Fishman planned it or the board imposed it doesn’t change the fundamental asset thesis at all. The sulopenem patent estate, the FDA approval, the clinical data, the cUTI opportunity — none of that depends on whether Fishman was a strategic genius or a desperate CEO who got fired.
0 · Reply
Gur001
Gur001 Aug. 3 at 7:42 AM
$ITRM Whats the update on liquidation guys? I been busy for last 3 weeks. please let me know in few words. Are we done or there is still hope 🙏
1 · Reply
Amb8675309
Amb8675309 Aug. 3 at 4:27 AM
$ITRM The relationship between the board and Teneo almost certainly predated the March 27 filing — boards in this situation engage restructuring advisors weeks or months before a public filing. That engagement was at the board level, not Fishman’s initiative. Fishman may not have been fully in the loop on the liquidation planning until relatively late. The “planned controlled transfer” framing that Stocktwits users found compelling was reading strategic intent into what was actually a board-level decision made after management failed to achieve a bilateral sale. Teneo wasn’t Fishman’s plan B — Teneo was the board’s plan after Fishman’s plan A failed.
2 · Reply
Amb8675309
Amb8675309 Aug. 3 at 4:23 AM
$ITRM revised thesis: BOD lost patience with CF & decided to go to liquidation- which eliminates the CEO/CFO positions- aka he “resigns”. Why? Maybe he’s not a tactical genius: 1) He took the RLN deal in Jan/2020, with NO CRL protection clause & an 8x CoC multiplier=structurally terrible deal that left the company catastrophically exposed to exactly the scenario that materialized( a CRL). 2) After the 2021 CRL for the uUTI, he did not pursue cUTI simultaneously(the far more VALUABLE market) & instead he spends 3 yrs & most of the co. remaining $ fixing the uUTI CRL. 3)He 🔥 10 months $ flow before launching via Eversana in 8/25, with approx. $11M in cash: an amount any experienced BP CEO would recognize as insufficient to fund a meaningful antibiotic launch to ➡️sustainable revenues. That is not the track record of a strategist. This was someone who was consistently behind the curve, making reactive decisions under capital pressure, and ultimately running out of road.
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 10:38 PM
$ITRM Shionogi coming in at 38%- highest match- same doctor writing IV script in hospital now can prescribe Orly- send patient home 2 days early- easy:have to sell one doctor on 2 different Shionogi meds if they buy Orly➡️less oral step down scripts for GSK/ Tebi. CEO of Shionogi committed to expanding US operations- whatever the cost. PFE doesn’t want GSK to win &just shelve cUTI Orly pathway➡️cuts down on PFE royalties- Better: Shionogi buys Orly- and now in outpatient setting all those new outpatient Shionogi reps have something other than a COVID-19 oral drug to sell. RLNs: most likely will walk away for a pay off of between $5-20Mil tops. Call it $80-100Mil to pay off all creditors. That leaves rest for shareholders. most shareholders happy and less likely to sue- maybe not me, but rest will be happy they put their hand in the fire and only singed their arm hairs.. $500MIL /52.8 Mil shares= $9.46/share Close to @yellowjacker estimates
2 · Reply
BTG007
BTG007 Aug. 2 at 9:51 PM
$ITRM threw all y’all’s numbers and theories into AI- that BARDA contract gives Shionogi the win-
1 · Reply
Toptopy
Toptopy Aug. 2 at 9:42 PM
$ITRM Effective on 01/08/2026 last update 29/07/2026
0 · Reply
EarlyRetirement0077
EarlyRetirement0077 Aug. 2 at 9:18 PM
$ITRM why am I not a millionaire already?
1 · Reply
BTG007
BTG007 Aug. 2 at 9:08 PM
$ITRM the RLNs apparently did hire a lawyer- just look it up- you have to pay to see it- anyways, they hired an expensive attorney for a reason- no one works on a case if it’s just about 100K
1 · Reply
Amb8675309
Amb8675309 Aug. 2 at 6:07 PM
$ITRM “The combination of those factors running in parallel, each requiring separate counsel in multiple jurisdictions, each with its own negotiating dynamics and internal approval requirements, is entirely consistent with a 4-6 month process timeline that has not yet produced a public announcement. The absence of news is most consistent with a process that is genuinely complex and still running — not one that has failed. The billing hours observation remains the most important single signal that real money is being negotiated over. Lawyers of his caliber do not spend four months on a $120,000 claim”.
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 5:59 PM
$ITRM likely causes of the delay by %age probability: RLN settlement negotiation & release structure: 35-40% Multi-party bidding process and due diligence: 30-35% PFE consent negotiation parallel work stream: 15-20% Entity-by-entity IP transfer and regulatory mechanics: 10-15%
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 5:53 PM
$ITRM what’s the likely cause of the amount of time it’s taken: It’s a combo of RLNs negotiating for as much as they can + there’s hopefully a multiple bidder process ongoing. Neither the RLN dispute alone nor the competitive bidding process alone fully explains four months of silence. It requires both simultaneously — a genuine competitive process that would take time regardless, complicated by a creditor dispute that adds legal complexity every serious buyer requires to be resolved before closing.
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 5:51 PM
$ITRM dig a little bit deeper-There are at least 5 arguments the RLN attorney can make. THE RELEASE VALUE ARGUMENT Even if the other 4 legal claims fail on the merits, their most powerful practical argument is commercial rather than legal. The argument: “Our clients hold a contractual instrument that runs to 2045 and references 15% of all US sulopenem revenues up to $414M. Any buyer acquiring this asset faces uncertainty about successor liability, CoC provisions, and covenant breach claims under New York law. That uncertainty has real commercial value to a buyer who needs clean representations and warranties, clean purchase accounting, and clean board approval. Our clients’ release of all claims — including every argument listed above — has a market value far exceeding $120,000 in principal. We are entitled to negotiate that release value.”
0 · Reply
Biorocksme
Biorocksme Aug. 2 at 4:14 PM
$ITRM Regarding the Aug/sept closed court session. ——Liquidator Operations Continue: The appointed court liquidators (e.g., Joint Liquidators from Teneo) maintain full authority to negotiate asset sales, process non-binding or binding bids for intellectual property (including the Orlynvah patent portfolio), sign purchase agreements, and draft administrative reports. Urgent Sittings Available: If an asset sale or liquidator petition requires immediate court sanction during the recess, a designated High Court Duty Vacation Judge sits in Dublin (Court 6, Four Courts) specifically to hear certified urgent applications. Public Announcements: Information, regulatory updates, or liquidator notices regarding patent bids or wind-down milestones can still be filed or issued at any time during August and September without waiting for Michaelmas Term (October).
1 · Reply
yellowjacker
yellowjacker Aug. 2 at 3:47 PM
$ITRM There are no bonuses or golden parachutes. There are no 414M liabilities on the RLNs. There is no more Fishman and Board. There is Orlynvah and about 80M in total liabilities.😃
3 · Reply
Amb8675309
Amb8675309 Aug. 2 at 9:05 AM
$ITRM advice CF should have taken to heart: 1) Never tell a lie; Always be honest 2) Care about your customers first and your shareholders second. 3) CEO comes third. Bob Duggan, former CEO of Pharmacyclics, which he sold for $21BIL to AbbVie, in 2015. https://youtube.com/shorts/6pUKBKgNav4?is=dPQdvPoDm_AnSRex
2 · Reply
Amb8675309
Amb8675309 Aug. 2 at 2:57 AM
$ITRM so look at it this way: there’s over $500 million of sunk costs +11 years spent➡️into the approval for this drug as a uncomplicated UTI oral medicine and the only thing on paper that the public got to see was $390,000 of sales. so for this liquidation to go on this long, it’s got to be about the potentiality of the complicated step down and the volume play on the worldwide uUTI use at a much lower price, plus BARDA in the future, and Anthrax- wow what a money pit so far- it’s up there with the theory in astrophysics that there’s a black hole at the center of the universe and it’s actually Corey Fishman and ITRM, sucking in all the money that gets too close
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 2:48 AM
$ITRM and a big number like 500 million+ most likely still triggers a CoC bonus because that was up to Teneo to honor that and I’m sure it was quid pro quo if they wanted this client. then by the time that everyone takes their pound of flesh, those of us that bought at a dollar or more. We’re going to end up seeing very little, but Fishman has unvested options that vest after a sale, plus the change of Control bonus, plus salary- he makes out like a bandit and we still feel like it’s not a lot of payoff for 18 months/2 years/4 years of dealing with his ineptitude
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 2:40 AM
$ITRM look my goal is somewhere between 400 and 600 but that doesn’t help us if RL ends make the case and succeed in getting 414 or even half of that and then you’ve got a Pfizer fee that’s triggered. That’s the sub license fee and then you have all the goddamn lawyers it could still end up being $.50 if they don’t wrap this up so a top line number that sounds amazing and we still see nothing Burger in our account/ 
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 2:25 AM
$ITRM and whether you’re using it off label for step down therapy until it’s approved or using it in uUTIs, if insurance doesn’t cover it, someone has to foot the bill. With uUTIs if medical exception doesn’t work and they still insist on prior off you’re just creating a stronger and stronger super bug while destroying the woman’s got micro biome again. Insurance companies are ruthless about this but that’s how they are. It’s all about the money. Contrast this on the complicated UTI side: the insurer may make exceptions if the Dr really wants to use Orly versus Tebi because getting that patient out of the hospital two days early is such a huge savings for the insurance company.
0 · Reply
Amb8675309
Amb8675309 Aug. 2 at 2:20 AM
$ITRM because you type the pathogen before you run an IV according to an anesthesiologist I spoke with, (we could see hospital lab volume in the Dallas area when we were looking at buying several labs) you’ll know pathogen so no empirical use of Orly in cUTI step down. You’re matching the pathogen with the right drug, so in approximately 18 months if this closed tomorrow, a BP could be on their way to having Orly approved as cUTI step down therapy.. Like Fishman said: there’s a very well-known saying an infectious disease medicine: give the right patient the right drug at the right time- so on a step down therapy if you already know what pathogen patient has, you match the oral drug to the already identified bug-then the step down logically for any of the ESBL pathogens causing cUTIs will be to continue at home with Orlynvah- i’ve spoken with a couple doctors who said that they intend to do this off label for now. Challenge: FDA may protest this use and demand phase 3 study.
0 · Reply